Uncategorized

While an improvement from the skin substitute coverage policies that have been delayed since Nov. 2024, CMS’s updated intentions risk prolonging uncertainty for the likes of CTEC.LN, MDXG, and ORGO, as well as benefits for…

Coming roughly in line with our timing expectations outlined in early June (admittedly, a quarter or so early), we would expect CMS’s reopening of its transcatheter aortic valve replacement (TAVR) coverage policy to provide greater…

This is the last week the House and Senate will be in session until the week of January 5. Hence, we see some notable items that investors should be interested in:   House vote on a…

Having received a large number of questions on whether Medicare Administrative Contractors (MAC) might refuse to cover INSP’s Inspire V device under CPT 64568 following CMS’s recent facility rate increase via assignment to a New…

We see growing uncertainty for the trajectory of defense spending beyond FY26 due to several policy-related crosscurrents:  Recent comments from OMB Director Russ Vought signaling potential use of a reconciliation bill next year to increase…

Given today’s weakness in HIMS following the introduction of a drug compounding pharmacy oversight bill (HR 6509) by Reps. Rudy Yakym (R-IN) and André Carson (D-IN), we have received some inbound questions about the near-term…

With shares of INSP up ~60% since CMS announced a 48% hospital rate increase for Inspire V procedures billed under CPT 64568 in CY26 (+58% for ASCs), we continue to believe that this will be…

Yesterday’s announcement by the White House to allow Nvidia (NVDA to sell the H200 chip to China reinforces our view that there’s an out of consensus 40-50% probability that NVDA could sell the more advanced…

The House and Senate are in session for the next two weeks before taking off for the rest of the year. As for this week, we see the following items that could be important to…

The recent fits-and-starts for around a compromise to avert expiration of the ACA enhanced premium tax credits (eAPTCs) at year-end unsurprisingly remains stalled, with no meaningful concessions from either side’s leaders. As we head into…